Longitudinal changes in bone mineral density after initiation of elexacaftor-tezacaftor-ivacaftor in youth and adults with cystic fibrosis: PROMISE-ENDO
Abstract
BACKGROUND: ) in the 24-30 months (mos) following ETI initiation. METHODS: Participants had CF, ≥1 F508del mutation, and were aged ≥12 years (y). Dual-energy X-ray absorptiometry (DXA) scans of the WB, LS, TH, and FN were collected before and following 12-18 mos and 24-30 mos of ETI therapy. Changes in aBMD Z-scores (aBMDZ) were examined with longitudinal mixed effects models. RESULTS: Baseline aBMDZ was below-average at all skeletal sites in youth and adults (aBMDZ -0.11). CONCLUSIONS: Youth aBMDZ was lower at multiple skeletal sites 12-18 mos after ETI initiation, and these changes persisted at 24-30 mos. Adult aBMDZ generally remained unchanged.
Fields of Study & Subjects
Cystic Fibrosis Research Advances
Pharmacological Effects and Toxicity Studies
Bone health and osteoporosis research
Publication details
- Journal / source
- Journal of Cystic Fibrosis
- Volume
- 25
- Issue
- 3
- Pages
- 457–465
- Publication date
- 30 January 2026
- Language
- EN